financetom
Business
financetom
/
Business
/
Temu, Shein targeted as EU cracks down on unsafe ecommerce imports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Temu, Shein targeted as EU cracks down on unsafe ecommerce imports
Feb 5, 2025 3:06 AM

BRUSSELS, Feb 5 (Reuters) - Chinese online marketplace

Temu and fast-fashion retailer Shein will be liable for the sale

of unsafe and dangerous products on their platforms, the

European Commission said on Wednesday as part of a crackdown

against the flood of cheap ecommerce imports into the European

Union.

The EU executive also said it would coordinate a joint

investigation by the Consumer Protection Cooperation (CPC)

Network of national consumer authorities into Shein based on

suspicions that the company infringes EU consumer protection

rules.

The measures by the EU executive echoed a similar push by

the U.S. government which ended a trade provision this week used

by retailers including Temu and Shein to ship low-value packages

duty-free to the United States.

The Commission said its concerns were triggered by some 4.6

billion low-value items below 22 euros imported into the EU last

year, equal to 12 million parcels per day, 91% of which came

from China. The figure was double that in 2023.

It said the cheap imports pose unfair competition to EU

sellers which follow the rules while the large number of

packages being shipped has a negative impact on the environment

and climate.

"We want to see a competitive e-commerce sector that keeps

consumers safe, offers convenient products, and is respectful of

the environment," EU tech chief Henna Virkkunnen said in a

statement.

Shein said it would engage with the consumer agencies and

the Commission.

"We share the CPC Network's goal of ensuring European

consumers can shop online with peace of mind, and we intend to

work closely with the CPC Network and the Commission to address

any concerns," a spokesperson said.

Temu did not immediately respond to a request for comment.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer Stocks Mixed Pre-Bell Monday
Sector Update: Consumer Stocks Mixed Pre-Bell Monday
Jul 8, 2024
09:07 AM EDT, 07/08/2024 (MT Newswires) -- Consumer stocks were mixed pre-bell Monday with the Consumer Staples Select Sector SPDR Fund ( XLP ) 0.1% higher and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) down 0.2% recently. International Game Technology ( IGT ) was up more than 2% after saying it has made its popular Prosperity Link...
Hungary's government seeks more corporate contributions, media funding limits
Hungary's government seeks more corporate contributions, media funding limits
Jul 8, 2024
* Hungary places measures in context of Ukraine war * Government has previously sought budget contributions * Plans to send back foreign funds given to Hungarian media * Orban met Xi on Monday, Putin on Friday (Updates throughout with media funding legislation; adds paragraphs 1-2, 6-9) By Boldizsar Gyori and Anita Komuves BUDAPEST, July 8 (Reuters) - Hungary's government laid...
Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate
Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate
Jul 8, 2024
09:06 AM EDT, 07/08/2024 (MT Newswires) -- Merus (MRUS) said Monday it has dosed first patient in its phase 2 trial of petosemtamab combined with standard chemotherapy to treat second-line metastatic colorectal cancer. The open-label trial aims to evaluate the safety and preliminary antitumor activity of petosemtamab and chemotherapy in approximately 40 patients without prior EGFR inhibitor treatment. ...
Outlook Therapeutics Receives UK Marketing Authorization for Eye Disease Drug
Outlook Therapeutics Receives UK Marketing Authorization for Eye Disease Drug
Jul 8, 2024
09:08 AM EDT, 07/08/2024 (MT Newswires) -- Outlook Therapeutics ( OTLK ) said Monday that the UK health regulator has granted marketing authorization for Lytenava, an ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration. The European Commission recently granted marketing authorization for Lytenava for the same indication and the company said it expects a commercial drug launch in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved